8-K: Aptose Biosciences Amends Acquisition Deal, Secures New Funding

Aptose Biosciences Inc. has amended its arrangement agreement with Hanmi Pharmaceutical, postponing its shareholder meeting to March 31, 2026, and securing an additional US$11.1 million uncommitted facility to advance Tuspetinib development.

Summary

• Aptose Biosciences Inc. entered into an Amended and Restated Arrangement Agreement with Hanmi Pharmaceutical Co. Ltd. and HS North America Ltd. (Hanmi Purchaser) for the acquisition of Aptose shares not currently owned by Hanmi Purchasers.
• The special meeting of shareholders, originally scheduled for January 16, 2026, has been postponed and reconvened to March 31, 2026, at 11:00 a.m. (EST) to address comments from the U.S. Securities and Exchange Commission (SEC).
• The new record date for the Reconvened Meeting is February 24, 2026.
• Aptose's board of directors unanimously recommends that shareholders vote FOR the special resolutions approving the Continuance and the Arrangement.
• Aptose also entered into a US$11.1 million Second Amended and Restated 2025 Facility Agreement with Hanmi, which is uncommitted and administered through multiple advances until May 31, 2026.
• The funds from this facility will be used to cover business and clinical operations expenses related to the advancement of Tuspetinib.
• No single advance under Facility #3 will exceed US$2,000,000, and any unpaid principal will accrue interest at six percent (6%) per annum.
• The facility agreement is considered a related-party transaction, for which Aptose is relying on the financial hardship exemption under Multilateral Instrument 61-101.
• The acquisition consideration is CAD$2.41 in cash per common share.
• All outstanding Incentive Securities (Options, RSUs) and Warrants (excluding Armistice Warrants) will be exchanged for cash based on the Consideration less the exercise price, or the Black Scholes Amount for Armistice Warrants.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mixed development. While securing additional funding is positive for operations, the uncommitted nature of the facility and the delay in the acquisition due to SEC comments introduce significant uncertainty and suggest underlying financial challenges.

Positives

• Secured an additional US$11.1 million in funding from Hanmi, which is crucial for the ongoing development of Tuspetinib, particularly for the Triplet Study in AML.
• The board of directors unanimously recommends the acquisition, suggesting favorable terms for shareholders (excluding Hanmi Purchasers) and a clear path forward for the company.
• The funding helps maintain key resources necessary to conduct the clinical trials for the Triplet Study.

Negatives

• The shareholder meeting was postponed from January 16, 2026, to March 31, 2026, due to SEC comments, indicating regulatory hurdles and potential delays in the acquisition process.
• The US$11.1 million facility is 'uncommitted and fully discretionary,' meaning Hanmi is not obligated to provide the funds, introducing uncertainty regarding its actual availability.
• Aptose is relying on a 'financial hardship exemption' for the related-party facility agreement, suggesting a precarious financial position and potentially limited alternatives for funding.
• The consideration of CAD$2.41 per share may be viewed as low by some shareholders, depending on their entry price and long-term expectations.

Risks

• The transaction may not be completed on the terms and conditions, or on the timing, currently contemplated, or at all, due to a failure to obtain or satisfy required regulatory, shareholder, and court approvals or for other reasons.
• There is a risk that competing offers or acquisition proposals will be made.
• Failure to complete the transaction for any reason could have a negative impact on the price of Aptose's common shares or on its business.
• Hanmi Purchasers' failure to pay the cash consideration at the completion of the transaction.
• Aptose's business may experience significant disruptions, including loss of employees, due to transaction-related uncertainty, industry conditions, or other factors.
• Risks relating to employee retention.
• The risk of regulatory changes that may materially impact Aptose's business or operations.
• Diversion of management's attention from Aptose's ongoing business operations while the transaction is pending.

Future Outlook

The company aims to continue advancing Tuspetinib, particularly in frontline triplet therapy for newly diagnosed AML, supported by the new facility agreement. The acquisition by Hanmi is pending shareholder and regulatory approvals, with the shareholder meeting now scheduled for March 31, 2026.

Management Comments

• Aptose's board of directors unanimously recommends that the shareholders vote FOR the special resolutions approving the Continuance and the Arrangement at the Reconvened Meeting.
• The board of directors, acting in good faith and having taken into account the liquidity, financial position, and cash needs of the Company, the alternatives available, relevant benefits, risks, and other factors, unanimously determined that entering into the September 2025 and December 2025 amended and restated facility agreements will improve the Company's financial position and that their terms are reasonable in Aptose's circumstances.

Industry Context

StockSavvy.ai notes that the continued funding for Tuspetinib development underscores the ongoing industry focus on novel therapies for acute myeloid leukemia (AML), a challenging hematological malignancy. The acquisition by Hanmi Pharmaceutical, a larger entity, reflects a trend of consolidation and strategic partnerships in the biotechnology sector, where smaller clinical-stage companies often seek larger partners for financial stability and broader market access. The regulatory scrutiny from the SEC highlights the rigorous oversight in M&A transactions involving publicly traded companies, particularly those with complex financial structures or related-party elements.

Comparison to Industry Standards

• The CAD$2.41 per share consideration should be benchmarked against recent acquisitions of clinical-stage oncology companies, especially those with assets in similar development phases for AML. For example, comparing the premium offered over Aptose's pre-announcement share price to typical premiums in biotech M&A (often 30-50% or more).
• The 6% interest rate on the US$11.1 million facility should be compared to prevailing market rates for similar-risk, uncommitted debt financing for clinical-stage biotech companies, which often face higher borrowing costs due to inherent R&D risks.
• The reliance on a 'financial hardship exemption' for related-party transactions, while permitted, suggests a more distressed financial situation than typically seen in robust biotech firms, potentially indicating a lower bargaining power for Aptose compared to industry peers in a stronger cash position.

Corporate Governance

Legal Proceedings

• The filing identifies 'Transaction Litigation' as a risk, referring to any suit, claim, action, charge, litigation, arbitration, or other proceeding commenced by a third party against or involving the Corporation, its Board, or officers relating to the Arrangement. Aptose will notify the Purchaser of any such litigation and allow participation in its defense.

Related Party Transactions

• The Second Amended and Restated 2025 Facility Agreement for US$11.1 million with Hanmi Pharmaceutical Co. Ltd. is a related-party transaction, as Hanmi is a related party of Aptose under Canadian securities laws.
• Aptose is relying on the financial hardship exemption from formal valuation and minority shareholder approval requirements under MI 61-101 for this facility agreement.
• The board of directors unanimously determined that the terms of the September 2025 and December 2025 amended and restated facility agreements were reasonable and would improve the company's financial position.

Stakeholder Impact

• Shareholders: Will vote on the acquisition and, if approved, those not owned by Hanmi Purchasers will receive CAD$2.41 per share. Dissenting shareholders have specific rights.
• Employees: The filing notes risks of significant business disruptions, including loss of employees due to transaction-related uncertainty and challenges in employee retention. Existing employment contracts and benefits will be honored for a period of twelve (12) months following the Effective Time.
• Creditors: Hanmi Pharmaceutical is a significant creditor through the facility agreements. The facility agreement specifies that Hanmi's obligations rank senior in right of priority and payment to all other obligations, liabilities, and indebtedness of the Loan Parties, except for obligations mandatorily preferred by law.

Next Steps

• Mailing of the definitive proxy statement to shareholders as soon as practicable.
• Holding the Reconvened Meeting on March 31, 2026, for shareholders to vote on the Continuance and Arrangement Resolutions.
• Aptose expects to receive the first advance from the US$11.1 million facility soon.
• Continued advancement of Tuspetinib, including the expansion of clinical studies.
• Delisting of Shares from the TSX and deregistration with the SEC as promptly as practicable following the Effective Time.

Key Dates

Recommendation

The acquisition at CAD$2.41 per share provides a clear exit for shareholders, but the delay and the uncommitted nature of the new funding introduce uncertainty. While the board recommends the deal, the 'financial hardship' exemption suggests limited alternatives. Investors should hold to see if the acquisition closes as planned, as the current price likely reflects the offer, but be aware of the risks of non-completion and the company's underlying financial fragility.

Keywords

Aptose Biosciences, Hanmi Pharmaceutical, Acquisition, Arrangement Agreement, SEC Filing, Tuspetinib, AML, Clinical Trials, Biotechnology, Oncology, Corporate Governance, Related Party Transaction, Facility Agreement, Shareholder Meeting, Merger, Delisting, APS, APTOF